Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens

[-] TrumpLyftAlles | 3 points | May 23 2020 15:02:08

This is another hit piece apparently based on the Monash 48 hours "Concentration is too high!".

The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the present report the in vitro antiviral activity end-points are analyzed from the pharmacokinetic perspective. The available pharmacokinetic data from clinically relevant and excessive dosing studies indicate that the SARS-CoV-2 inhibitory concentrations are not likely to be attainable in humans.

[-] kunkr | 3 points | May 23 2020 15:18:24

I don't agree with their opinion, I think that inhibitory concentrations are likely to be attainable with similar doses given for river blindness (200mcg/Kg). You can't base human dosage on a test done in vitro.

[-] rraak | 3 points | May 23 2020 15:37:06

It's another example of poor assertions based on thinking a treatment is either 0% or 100% effective based on in vitro findings, and that attaining the appropriate "inhibitory concentration" is the goal. I've even some take it to the extreme of thinking it can't be effective unless it's nebulized and inhaled directly into the lungs... as if the point of entry into the body / direct topical application is the most important thing... ignoring the systemic effects.

[-] TrumpLyftAlles | 2 points | May 23 2020 15:42:19

You can't base human dosage on a test done in vitro.

Exactly! It's so frustrating, because ivermectin has been shown to be effective already by the Usefulness study. I guess it's a cheap and easy publication, echo the stuff that was in the letters accompanying the Lancet publication of the Monash study.

Peculiar to ivermectin (as far as I know, but I don't no anything about other drugs) is its ability to inhibit parasites years after a single ordinary dose. It changes something in the human body. With the two main parasite targets, river blindness and lymphatic filariasis, a once-a-year dose is sufficient even though the half-life of the drug is just 16 hours. That quality makes me really hopeful that the trials demonstrate effectiveness against covid19. Imagine ivermectin as part of back-to-school prep and the annual physical. IF IT WORKS!

[-] kunkr | 2 points | May 23 2020 17:24:32

We have to remember that there are many fuck heads who see the pandemic as a way to make money, which unfortunately our system allows (making money off of life saving medication). Luckily there are trials going on and other countries are already starting to use it, I'm just waiting for the results.

[-] TrumpLyftAlles | 2 points | May 23 2020 17:32:51

and other countries are already starting to use it

I know that the MDs and other staff are frantically busy saving lives. They're also generally applying their best therapies, so they can't have a control group. The recent news out of Bangladesh is an example. Great results! But there's no way to prove anything from that experience. So it's "Ivermectin works! (maybe)".

I'm just waiting for the results.

Patience! The truth is out there! :)

[-] TrumpLyftAlles | 1 points | May 23 2020 15:07:09

Georgi Momekov is one of the co-authors.

Medical University of Sofia
Faculty of Pharmacy
Department of Pharmacology, Pharmacotherapy and Toxicology
Ph.D., Professor

Sofia is in Bulgaria.

Pretty good credentials!

[-] okayatarter | 1 points | May 23 2020 19:37:44

Did the doc in Florida submit is study? Could you find it somewhere? Here’s a recent article https://www.newsmax.com/t/newsmax/article/968688

[-] TrumpLyftAlles | 1 points | May 24 2020 05:43:54

That article is posted to the sub (twice). It says the doc submitted it. Haven't found it so far.